Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 (durvalumab) in Myelodysplastic Syndrome
NCT02117219Phase 1Completed
- Sponsor
- MedImmune
- Start
- May 2014
- Primary completion
- Apr 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 4
01
Overview
Phase 1, open-label trial of durvalumab in myelodysplastic syndrome (MDS) (3 arms), sponsored by MedImmune. Primary endpoints: Dose Limiting Toxicities at 180 days and Subject's safety overall at 730 days. Started May 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02117219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117219.